nexbio
inc
san
diego
california
usa
obtain
emerg
investig
new
drug
applic
approv
us
food
drug
administr
univers
washington
institut
review
board
patient
provid
written
inform
consent
administ
inhal
dri
powder
emit
dose
mg
daili
day
use
oral
inhal
cyclohal
teva
pharmaceut
ltd
north
wale
pennsylvania
usa
inhal
albuterol
administ
dose
oropharyng
wash
sampl
obtain
standard
manner
start
therapi
daili
therapi
subsequ
time
hospit
discharg
monitor
respons
treatment
sampl
place
ml
viral
transport
media
analyz
via
quantit
polymeras
chain
reaction
pcr
univers
washington
molecular
virolog
laboratori
plasma
sampl
also
analyz
via
quantit
pcr
woman
histori
interstiti
pulmonari
fibrosi
ipf
diagnos
year
earlier
underw
right
lt
month
present
cours
complic
episod
humor
reject
day
post
transplant
treat
ivig
plasmapheresi
cyclophosphamid
sinc
time
initi
complic
well
requir
supplement
oxygen
unabl
toler
mycophenol
mofetil
azathioprin
immunosuppress
regimen
time
admiss
includ
tacrolimu
prednison
mg
daili
ongo
antimicrobi
medic
includ
acyclovir
azithromycin
clotrimazol
two
week
admiss
patient
husband
develop
symptom
bronchiti
week
admiss
patient
develop
malais
sore
throat
nasal
congest
treat
empir
two
day
admiss
becam
increasingli
dyspneic
develop
cough
product
yellow
sputum
two
day
later
oxygen
satur
ambient
air
admit
admiss
afebril
requir
l
supplement
oxygen
maintain
oxygen
satur
laboratori
result
notabl
mild
leukopenia
tabl
cytomegaloviru
detect
plasma
pcr
two
set
blood
cultur
steril
comput
tomographi
scan
chest
show
diffus
opac
throughout
right
lung
interlobular
septal
thicken
small
right
pleural
effus
left
nativ
lung
show
unchang
honeycomb
traction
bronchiectasi
consist
known
histori
ipf
initi
treat
ceftriaxon
oseltamivir
follow
day
bronchoscopi
reveal
erythemat
easili
collaps
airway
diffus
thin
secret
throughout
right
lung
consist
tracheobronch
cultur
bronchoalveolar
lavag
bal
neg
bacteria
fungi
legionella
mycobacteria
urin
legionella
antigen
neg
bal
fluoresc
antibodi
fa
pneumocysti
jirovecii
pneumonia
pcr
aspergillu
fumigatu
cytomegaloviru
rsv
shell
vial
cultur
pcr
bocaviru
human
metapneumoviru
piv
type
rsv
influenza
b
coronaviru
rhinoviru
adenoviru
neg
bal
nasopharyng
swab
fa
pcr
posit
piv
type
plasma
sampl
taken
hospit
day
show
evid
piv
viremia
hospit
day
transfer
intens
care
unit
increas
hypoxia
fig
base
bal
result
oseltamivir
ceftriaxon
discontinu
immunosuppress
markedli
chang
hospit
day
treatment
initi
begin
fifth
day
therapi
hospit
day
signific
reduct
seen
detect
piv
copi
fig
hospit
day
piv
longer
detect
oropharyng
wash
lower
limit
detect
viral
copiesml
day
treatment
hospit
day
began
feel
subject
improv
decreas
dyspnea
cough
hospit
day
wean
facemask
nasal
cannula
use
l
supplement
oxygen
maintain
satur
high
note
persist
dyspnea
exert
longer
rest
throughout
hospit
cours
laboratori
valu
signific
slight
rise
alkalin
phosphatas
tabl
one
week
hospit
discharg
note
increas
dyspnea
desatur
ambul
increas
oxygen
requir
l
rest
spirometri
forc
vital
capac
fvc
l
predict
forc
expiratori
volum
l
markedli
decreas
prior
assess
month
earlier
fvc
l
l
repeat
bronchoscopi
show
cellular
reject
found
antidonor
antibodi
serum
treat
methylprednisolon
plasmapheresi
ivig
rituximab
improv
symptom
oxygen
requir
l
time
discharg
respiratori
viral
fa
pcr
bal
detect
evid
piv
viral
infect
repeat
spirometri
week
post
discharg
show
improv
result
prior
although
still
impair
baselin
fvc
l
l
report
case
lt
recipi
treat
sever
pneumonia
evid
patient
piv
may
caus
sever
lung
diseas
hct
lt
recipi
diffus
involv
transplant
lung
mark
symptom
high
oxygen
requir
nearli
prompt
intub
although
copathogen
may
commonli
found
associ
piv
immunocompromis
host
addit
pathogen
identifi
patient
effect
therapi
avail
treat
piv
new
activ
agent
clearli
need
vitro
vivo
activ
piv
use
describ
small
number
transplant
recipi
patient
dramat
declin
seen
quantit
viral
oropharyng
sampl
start
day
therapi
diminut
undetect
level
day
overal
indic
declin
viral
load
reduct
piv
viral
load
appear
correl
symptomat
improv
reduct
oxygen
requir
notabl
addit
antivir
therapi
use
immunosuppress
therapi
significantli
chang
period
associ
may
exist
respiratori
viral
infect
subsequ
develop
acut
chronic
reject
interestingli
acut
reject
diagnos
shortli
infect
patient
evid
recurr
piv
subsequ
respond
addit
immunosuppress
treatment
clear
degre
reject
contribut
initi
sever
lung
process
mark
clinic
improv
without
chang
immunosuppress
therapi
like
reject
predomin
featur
initi
patient
toler
well
treatment
common
see
mild
increas
alkalin
phosphatas
level
thought
relat
delay
clearanc
secondari
system
protein
desialyl
seen
patient
promptli
resolv
discontinu
drug
toxic
evid
three
patient
describ
previous
includ
hct
recipi
lt
recipi
compar
previous
report
case
patient
lung
involv
dramat
sever
high
oxygen
requir
initi
oropharyng
wash
piv
viral
load
patient
similar
one
hct
patient
appreci
higher
found
patient
demonstr
much
greater
declin
piv
viral
load
compar
rel
small
chang
seen
previous
describ
lt
recipi
use
inhal
albuterol
prior
dose
attempt
optim
local
drug
deliveri
say
made
signific
differ
patient
respons
present
formul
readili
use
ventil
patient
one
obviou
limit
report
descript
singl
patient
thu
difficult
know
true
benefit
oppos
simpli
natur
resolut
infect
howev
rapid
larg
log
virolog
declin
seen
patient
appear
correl
clinic
improv
suggest
potent
specif
antivir
effect
result
clinic
benefit
addit
prolong
viral
shed
piv
infect
commonli
seen
immunocompromis
patient
patient
clearanc
viru
fairli
quickli
treatment
suggest
vivo
antivir
effect
abl
start
treatment
day
initi
diagnosi
whether
earlier
treatment
would
led
rapid
improv
symptom
oxygen
clear
potenti
effect
earlier
treatment
graft
surviv
incid
bronchiol
obliteran
syndrom
present
case
suggest
well
toler
potent
vivo
antivir
effect
major
viral
pathogen
lt
recipi
given
potenti
acut
benefit
associ
treatment
piv
infect
solid
organ
transplant
hct
recipi
futur
control
trial
popul
warrant
